Clinical Trials in Developing Countries
How to protect people against unethical practices?
European legislation regulating the marketing authorisation of medical products states that results from clinical trials that do not meet the ethical requirements of Good Clinical Practice, cannot legally be used by an applicant to justify its application, irrespective of whether the trial was done inside or outside the EU. However, earlier studies indicate that this legislation is not always properly observed: these studies identified trials with an unethical design that were part of approved EU marketing applications. Clinical trials that are no longer accepted by Western European ethics committees are approved by the local ethics committees in countries like India, China, Argentina and Russia. Once officially approved by an ethics committee, there are no obstacles to including the trial in the technical dossier of a marketing application. In particular the ethical principles which are of utmost importance for developing countries, as reflected in the Declaration of Helsinki, are ignored by companies and regulatory authorities.
Meer informatie nodig?
-
Irene Schipper
Senior Onderzoeker
Publicatie
Related news
-
Datahonger wint het van medisch beroepsgeheim in Europese wet voor gezondheidsdataGeplaatst in categorie:OpinieIrene SchipperIrene Schipper
-
Maatschappelijke organisaties roepen de EU op om de belangen van patiënten en burgers centraal te stellen in de European Health Data SpaceGeplaatst in categorie:Gepubliceerd op:Verklaring
-
Bij kankermedicijn Trodelvy is alles gericht op de aandeelhoudersGeplaatst in categorie:Opinie